Breaking: Shire (LON:SHP) Outperform Rating Reiterated by equity analysts Bernstein Today; The Price Target is GBX 6000

Share

Shire (LON:SHP) Rating Reaffirmed

They currently have a GBX 6000 target on Shire (LON:SHP). The target price by Bernstein would suggest a potential upside of 32.07% from the company’s last stock close. This has been unveiled in a recent research report on Monday, 7 December.

From a total of 10 analysts covering Shire PLC (LON:SHP) stock, 11 rate it a ”Buy”, 0 a “Sell”, and 6 a ”Hold”. This means that 65% of the ratings are positive. The highest target price is GBX 96.71 while the lowest target price is GBX 81.77. The mean of all analyst targets is GBX 89.63 with a 18.46% above today’s (GBX 4548) stock price. Shire PLC was the topic of 80 analyst reports since July 24, 2015 according to the firm StockzIntelligence Inc. J.P. Morgan maintained shares on December 4 with “Overweight” rating. Credit Suisse maintained shares with “Neutral” rating and GBX 5400 target share price in a report from a November 4. Bernstein maintained SHP stock in a recent report from November 30 with “Outperform” rating. Barclays Capital maintained the rating on November 3. Barclays Capital has a “Overweight” rating and a GBX 5700 price target on shares. Finally, Berenberg maintained the stock with “Buy” rating in a report issued on a November 16.

Approximately 145,811 shares of stock traded hands. Shire PLC (LON:SHP) has declined 15.50% since May 8, 2015 and is downtrending. It has underperformed by 14.42% the S&P500.

Breaking: Shire (LON:SHP) Outperform Rating Reiterated by equity analysts Bernstein Today; The Price Target is GBX 6000

Shire plc is a biopharmaceutical company. The company has a market cap of 26.94 billion GBP. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. It has 13.38 P/E ratio. The Firm commercializes its products in the areas of Neuroscience, Gastrointestinal , Rare Diseases and Other therapeutic areas.

COMMENTS: